Shankar Musunuri Sells 100,000 Shares of Ocugen, Inc. (NASDAQ:OCGN) Stock

Ocugen, Inc. (NASDAQ:OCGN – Get Rating) CEO Shankar Musunuri sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $1.28, for a total transaction of $128,000.00. Following the transaction, the chief executive officer now directly owns 2,227,950 shares of the company’s stock, valued at $2,851,776. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ocugen Stock Performance

OCGN opened at $1.21 on Friday. Ocugen, Inc. has a 12-month low of $1.09 and a 12-month high of $4.53. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $264.85 million, a PE ratio of -3.46 and a beta of 3.97. The firm has a 50 day moving average of $1.39 and a two-hundred day moving average of $1.94.

Ocugen (NASDAQ:OCGN – Get Rating) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, analysts anticipate that Ocugen, Inc. will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Ocugen

A number of institutional investors have recently bought and sold shares of OCGN. State Street Corp grew its stake in shares of Ocugen by 108.0% during the 1st quarter. State Street Corp now owns 29,153,704 shares of the company’s stock worth $96,207,000 after purchasing an additional 15,136,085 shares during the period. Bank of America Corp DE grew its stake in shares of Ocugen by 199.0% during the 1st quarter. Bank of America Corp DE now owns 2,789,839 shares of the company’s stock worth $9,207,000 after purchasing an additional 1,856,804 shares during the period. UBS Group AG grew its stake in shares of Ocugen by 158.1% during the 1st quarter. UBS Group AG now owns 2,131,074 shares of the company’s stock worth $7,033,000 after purchasing an additional 1,305,248 shares during the period. Barclays PLC grew its stake in shares of Ocugen by 8,751.7% during the 3rd quarter. Barclays PLC now owns 1,202,242 shares of the company’s stock worth $2,140,000 after purchasing an additional 1,188,660 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Ocugen by 344.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 980,928 shares of the company’s stock worth $3,238,000 after purchasing an additional 760,306 shares during the period. 37.54% of the stock is owned by hedge funds and other institutional investors.

Ocugen Company Profile

(Get Rating)

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.